Q. Kang-Fortner

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

P. Fenaux, T. Cluzeau, J. Liesveld, 2020 .

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

T. Cluzeau, J. Liesveld, P. Rousselot, 2020 .

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

J. Carulli, M. McKeown, M. Eaton, 2022, Blood advances.